该股主要指标及行业内排名如下： 美好医疗2025年三季报显示，前三季度公司主营收入11.94亿元，同比上升3.28%；归母净利润2.08亿 元，同比下降19.25%；扣非净利润2.03亿元，同比下降17.85%；其中2025年第三季度，公司单季度主营 收入4.62亿元，同比上升2.56%；单季度归母净利润9390.02万元，同比上升5.89%；单季度扣非净利润 9270.68万元，同比上升9.56%；负债率11.43%，投资收益490.31万元，财务费用-2739.1万元，毛利率 39.34%。美好医疗（301363）主营业务：为全球医疗器械企业提供从产品设计开发到批量生产交付的 全流程一站式服务。 证券之星消息，截至2025年12月10日收盘，美好医疗(301363)报收于20.5元，上涨0.2%，换手率 1.06%，成交量3.96万手，成交额8104.59万元。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的 ...

人民财讯12月10日电，美好医疗（301363）12月10日在互动平台表示，脑机接口产品的成熟度和应用场 景随着下游客户产品的成熟和完善性能不断提高。公司正与下游脑机接口客户深入开展产品合作，协助 客户实现从实验室研发到批量出货的高效商业化转化，目前相关业务产生的收入规模较小。 ...

美好医疗在互动易平台回复投资者提问时表示，目前，侵入式脑机接口产品在植入材料选择、生物相容 性、自供电技术等关键领域与人工耳蜗高度相通。公司在脑机接口业务领域有着长期业务布局。具体来 看，在侵入式脑机接口领域，持续提升植入体组件的长期稳定性与生物相容性，推进材料安全性及排异 反应等方面的测试与优化，提供具备长期植入性、低排异、可量产、高可靠性的产品解决方案，并为非 植入组件提供集成化、小型化、便携式的产品研发制造支持。在半侵入式脑机接口领域，提供长期植入 产品方案，并配套相关手术辅助器械与耗材。在非侵入式脑机接口领域，提供小型化、便携性强、质量 稳定的产品组件与耗材。 美好医疗(301363)12月10日在互动易平台表示，公司已进入侵入式脑机接口产品的核心供应链，正与下 游脑机接口客户深入开展产品合作，协助客户实现从实验室研发到批量出货的高效商业化转化，目前已 产生小规模销售收入。未来将紧密追踪产业发展需求，全品类布局非侵入式、半侵入式、侵入式脑机接 口产品的核心供应链。 脑机接口产品的成熟度和应用场景随着下游客户产品的成熟和完善性能不断提高。美好医疗表示，公司 正与下游脑机接口客户深入开展产品合作，协助客户 ...

格隆汇12月10日丨美好医疗(301363.SZ)在互动平台表示，脑机接口产品的成熟度和应用场景随着下游 客户产品的成熟和完善性能不断提高。公司正与下游脑机接口客户深入开展产品合作，协助客户实现从 实验室研发到批量出货的高效商业化转化，目前相关业务产生的收入规模较小。 ...

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Insights - The 2025 National Medical Insurance and Commercial Health Insurance Innovation Drug Catalogs were released, adding 114 new drugs to the national insurance list, with a success rate of 88%, significantly higher than the previous year's 76% [2] - The first three quarters of 2025 saw a notable recovery in domestic innovative drug financing, with 324 financing events totaling $5.51 billion, a 67.6% increase year-on-year [3] - The flu positivity rate has not peaked yet, with a significant increase in flu cases, indicating a growing market for flu medications [4] - The report highlights breakthroughs in dual-target and new-target opportunities in the autoimmune field, with several companies making significant advancements [5] - There is a focus on inhalation formulations in respiratory diseases, with new drugs showing promising results [6] - Progress in liver-targeted small nucleic acids is noted, with companies like Arrowhead Pharmaceuticals making strides in this area [7] Summary by Sections 1. National Medical Insurance and Commercial Insurance Innovation Drug Catalogs - The 2025 catalog added 114 new drugs, including 50 innovative drugs, with a success rate of 88% [2] 2. Financing Trends and CXO Order Changes - Innovative drug financing events increased by 5.2% year-on-year, with total financing amounting to $5.51 billion [3] 3. Flu Positivity Rates - The flu positivity rate reached 51.1%, indicating a rising demand for flu medications [4] 4. Autoimmune Field Developments - Significant partnerships and advancements in dual-target drugs for autoimmune diseases were reported [5] 5. Inhalation Formulations in Respiratory Diseases - New inhalation drugs are showing positive clinical results, indicating a shift in treatment approaches [6] 6. Progress in Liver-Targeted Small Nucleic Acids - Arrowhead Pharmaceuticals achieved a milestone payment for its innovative RNA therapy, expanding its research pipeline [7] 7. Stock Recommendations - The report recommends stocks in various sectors, including inhalation formulations, small nucleic acids, and innovative drugs, highlighting specific companies for investment [8]

12月5日的资金流向数据方面，主力资金净流出933.9万元，占总成交额9.2%，游资资金净流入386.11万 元，占总成交额3.81%，散户资金净流入547.79万元，占总成交额5.4%。 证券之星消息，截至2025年12月5日收盘，美好医疗(301363)报收于21.42元，下跌0.46%，换手率 1.27%，成交量4.75万手，成交额1.01亿元。 美好医疗2025年三季报显示，前三季度公司主营收入11.94亿元，同比上升3.28%；归母净利润2.08亿 元，同比下降19.25%；扣非净利润2.03亿元，同比下降17.85%；其中2025年第三季度，公司单季度主营 收入4.62亿元，同比上升2.56%；单季度归母净利润9390.02万元，同比上升5.89%；单季度扣非净利润 9270.68万元，同比上升9.56%；负债率11.43%，投资收益490.31万元，财务费用-2739.1万元，毛利率 39.34%。美好医疗（301363）主营业务：为全球医疗器械企业提供从产品设计开发到批量生产交付的 全流程一站式服务。 该股最近90天内共有13家机构给出评级，买入评级11家，增持评级2家；过去90天内机构目标均 ...

证券之星消息，截至2025年12月4日收盘，美好医疗(301363)报收于21.52元，上涨1.03%，换手率 1.68%，成交量6.27万手，成交额1.34亿元。 12月4日的资金流向数据方面，主力资金净流入531.81万元，占总成交额3.98%，游资资金净流出457.73 万元，占总成交额3.43%，散户资金净流出74.08万元，占总成交额0.55%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-04 | 21.52 | 1.03% | 531.81万 | 3.98% | -457.73万 | -3.43% | -74.08万 | -0.55% | | 2025-12-03 | | 21.30 0.42% | 2118.31万 | 13.39% | 1423.55万 | 9.00% | -3541.86万 | -22.38% | | 2025-12-02 | | 21.2 ...

近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-03 | 21.30 0.42% | | 2118.31万 | 13.39% | 1423.55万 | 9.00% | -3541.86万 | -22.38% | | 2025-12-02 | 21.21 0.09% | | -200.72万 | -3.54% | 260.69万 | 4.59% | -59.96万 | -1.06% | | 2025-12-01 | 21.19 | -0.19% | -232.84万 | -3.84% | -20.18万 | -0.33% | 253.02万 | 4.17% | | 2025-11-28 | 21.23 | 0.66% | -121.73万 | -1.81% | 164.01万 | 2.43% | -42.29万 | -0.63% | | 2025-11-27 | 21.09 | 0 ...

证券之星消息，截至2025年12月2日收盘，美好医疗(301363)报收于21.21元，上涨0.09%，换手率 0.72%，成交量2.7万手，成交额5676.04万元。 12月2日的资金流向数据方面，主力资金净流出200.72万元，占总成交额3.54%，游资资金净流入260.69 万元，占总成交额4.59%，散户资金净流出59.96万元，占总成交额1.06%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-02 | 21.21 0.09% | | -200.72万 | -3.54% | 260.69万 | 4.59% | -59.96万 | -1.06% | | 2025-12-01 | 21.19 -0.19% | | -232.84万 | -3.84% | -20.18万 | -0.33% | 253.02万 | 4.17% | | 2025-11-28 | 21.23 0 ...

Group 1 - The 2025 Analyst Conference and the 7th Sina Finance "Golden Unicorn" Best Analyst Awards Ceremony were held in Shanghai, gathering over 300 industry experts to discuss future opportunities in the Chinese capital market [1] - The top honor for the 7th Sina Finance Golden Unicorn Elite Analyst in the innovative drug sector was awarded to the Zheshang Securities research team, led by Chief Analyst Wu Tianhao [1] Group 2 - The strategy for the high-value consumables sector in 2026 indicates optimism due to policy optimization, with expectations for revenue recovery and new product launches [2] - The medical device sector is expected to see performance recovery driven by the resumption of in-hospital bidding and the "Belt and Road" initiative, despite a decline in profit in the first three quarters of 2025 [2] - The home medical sector is anticipated to regain growth, supported by overseas expansion and recovery in revenue and profit growth in 2025 [2] Group 3 - Investment recommendations include high-value consumables companies with cleared procurement risks and new product launches, such as Microelectrophysiology, Aikang Medical, and Weikang Medical [3] - Medical device and home medical companies expected to see steady revenue growth include Mindray Medical, Meihua Medical, and Yuyue Medical, among others [3]